Assenagon Asset Management S.A. Trims Position in Lantheus Holdings, Inc. $LNTH

Assenagon Asset Management S.A. lowered its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 94.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 71,943 shares of the medical equipment provider’s stock after selling 1,208,111 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.11% of Lantheus worth $4,788,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Stanley Laman Group Ltd. grew its holdings in Lantheus by 38.7% in the 3rd quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock valued at $4,087,000 after buying an additional 22,229 shares during the period. Quantbot Technologies LP acquired a new position in shares of Lantheus during the 3rd quarter valued at about $1,847,000. American Assets Inc. acquired a new position in shares of Lantheus during the 3rd quarter valued at about $872,000. Campbell & CO Investment Adviser LLC purchased a new position in shares of Lantheus during the 3rd quarter worth about $2,184,000. Finally, Assetmark Inc. lifted its holdings in shares of Lantheus by 20.1% during the 3rd quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock worth $6,078,000 after acquiring an additional 19,844 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Stock Performance

Lantheus stock opened at $74.47 on Friday. The firm has a market capitalization of $4.85 billion, a PE ratio of 22.10 and a beta of -0.11. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $108.91. The stock’s 50 day moving average price is $72.49 and its 200 day moving average price is $63.33. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.51 and a current ratio of 2.70.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company had revenue of $406.79 million during the quarter, compared to the consensus estimate of $367.03 million. During the same quarter last year, the company earned $1.59 earnings per share. Lantheus’s revenue for the quarter was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of recent analyst reports. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Mizuho increased their price target on shares of Lantheus from $72.00 to $85.00 and gave the stock an “outperform” rating in a research note on Friday, February 27th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a report on Tuesday, February 24th. Jefferies Financial Group restated a “buy” rating and set a $110.00 price objective on shares of Lantheus in a report on Tuesday, March 17th. Finally, Truist Financial boosted their price target on Lantheus from $82.00 to $89.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and an average price target of $86.14.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.